Literature DB >> 10737379

Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion.

J H de Wilt1, T L ten Hagen, G de Boeck, S T van Tiel, E A de Bruijn, A M Eggermont.   

Abstract

Several possible mechanisms for the synergistic anti-tumour effects between tumour necrosis factor alpha (TNF-alpha) and melphalan after isolated limb perfusion (ILP) have been presented. We found a significant sixfold increase in melphalan tumour tissue concentration after ILP when TNF-alpha was added to the perfusate, which provides a straightforward explanation for the observed synergism between melphalan and TNF-alpha in ILP.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10737379      PMCID： PMC2374420          DOI： 10.1054/bjoc.1999.1032

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  28 in total

Review 1.  Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy.

Authors:  Alexander M M Eggermont; Timo L M ten Hagen
Journal:  Curr Oncol Rep       Date:  2003-03       Impact factor: 5.075

2.  Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability.

Authors:  Ferdy J Lejeune
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 3.  [Current state of neoadjuvant therapy of soft tissue sarcoma].

Authors:  M Lehnhardt; T Schmitt; M Bischof; A Daigeler; G Egerer
Journal:  Chirurg       Date:  2011-11       Impact factor: 0.955

4.  The diverse roles of the TNF axis in cancer progression and metastasis.

Authors:  Boram Ham; Maria Celia Fernandez; Zarina D'Costa; Pnina Brodt
Journal:  Trends Cancer Res       Date:  2016-01-01

Review 5.  Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?

Authors:  T Pencavel; R Seth; A Hayes; A Melcher; H Pandha; R Vile; K J Harrington
Journal:  Gene Ther       Date:  2010-05-06       Impact factor: 5.250

6.  Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours.

Authors:  G Spitaleri; R Berardi; C Pierantoni; T De Pas; C Noberasco; C Libbra; R González-Iglesias; L Giovannoni; A Tasciotti; D Neri; H D Menssen; F de Braud
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-17       Impact factor: 4.553

7.  Dynamic contrast-enhanced MRI using macromolecular contrast media for monitoring the response to isolated limb perfusion in experimental soft-tissue sarcomas.

Authors:  A Preda; P A Wielopolski; T L M Ten Hagen; M van Vliet; J F Veenland; G Ambagtsheer; S T van Tiel; M W Vogel; A M M Eggermont; G P Krestin; C F van Dijke
Journal:  MAGMA       Date:  2004-10-10       Impact factor: 2.310

8.  One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases.

Authors:  Dirk J Grünhagen; Flavia Brunstein; Wilfried J Graveland; Albertus N van Geel; Johannes H W de Wilt; Alexander M M Eggermont
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

Review 9.  Isolated limb infusion as a model to test new agents to treat metastatic melanoma.

Authors:  Michael E Lidsky; Paul J Speicher; Betty Jiang; Masahito Tsutsui; Douglas S Tyler
Journal:  J Surg Oncol       Date:  2013-11-20       Impact factor: 3.454

Review 10.  Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma.

Authors:  Cornelis Verhoef; Johannes H W de Wilt; Dirk J Grünhagen; Albertus N van Geel; Timo L M ten Hagen; Alexander M M Eggermont
Journal:  Curr Treat Options Oncol       Date:  2007-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.